Chengdu Zeling Biomedical Technology describes new PARP-1 inhibitors
Nov. 7, 2025
Chengdu Zeling Biomedical Technology Co. Ltd. has identified salts of deuterated compounds acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.